Nasopharyngeal neutrophilic-retention signatures could predict disease progression in early SARS-CoV-2 infection
© 2023 Wiley Periodicals LLC..
The nasopharynx is the initial site of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and neutrophils play a critical role in preventing viral transmission into the lower airways or lungs during the early phases of infection. However, neutrophil dynamics, functional signatures, and predictive roles in the nasopharynx of coronavirus disease 2019 (COVID-19) patients have not yet been elucidated. In this study, we carried out RNA sequencing of nasopharyngeal swabs from a cohort of COVID-19 patients with mild, moderate, severe outcomes and healthy donors as controls. Over 32.7% of the differentially expressed genes associated with COVID-19 severity were neutrophil-related, including those involved in migration, neutrophil extracellular traps formation, and inflammasome activation. Multicohort single-cell RNA sequencing analysis further confirmed these findings and identified a population of neutrophils expressing Vacuolar-type ATPase (V-ATPase) and the chemokine receptor CXCR4 in the nasopharynx. This population of neutrophils preferentially expressed pro-inflammatory genes relevant to phagosomal maturation as well as local reactive oxygen species and reactive nitrogen species production in the nasopharynx of patients with severe outcomes. A four-gene panel defined as a neutrophil signature associated with COVID-19 progression (NSAP) was identified as an early diagnostic predictor of severe COVID-19, which potentially distinguished severe patients from mild cases with influenza, respiratory syncytial virus, dengue virus, or hepatitis B virus infection. NSAP is mainly expressed on CXCR4high neutrophils and exhibits a significant association with the cell fraction of this neutrophil population. This study highlights novel potential therapeutic targets or diagnostic tools for predicting patients at a higher risk of severe outcomes.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
---|---|
Enthalten in: |
Journal of medical virology - 96(2024), 1 vom: 10. Jan., Seite e29328 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Qi, Furong [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adenosine Triphosphatases |
---|
Anmerkungen: |
Date Completed 27.12.2023 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1002/jmv.29328 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM366375725 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM366375725 | ||
003 | DE-627 | ||
005 | 20240214233030.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231227s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/jmv.29328 |2 doi | |
028 | 5 | 2 | |a pubmed24n1293.xml |
035 | |a (DE-627)NLM366375725 | ||
035 | |a (NLM)38146903 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Qi, Furong |e verfasserin |4 aut | |
245 | 1 | 0 | |a Nasopharyngeal neutrophilic-retention signatures could predict disease progression in early SARS-CoV-2 infection |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.12.2023 | ||
500 | |a Date Revised 14.02.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 Wiley Periodicals LLC. | ||
520 | |a The nasopharynx is the initial site of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and neutrophils play a critical role in preventing viral transmission into the lower airways or lungs during the early phases of infection. However, neutrophil dynamics, functional signatures, and predictive roles in the nasopharynx of coronavirus disease 2019 (COVID-19) patients have not yet been elucidated. In this study, we carried out RNA sequencing of nasopharyngeal swabs from a cohort of COVID-19 patients with mild, moderate, severe outcomes and healthy donors as controls. Over 32.7% of the differentially expressed genes associated with COVID-19 severity were neutrophil-related, including those involved in migration, neutrophil extracellular traps formation, and inflammasome activation. Multicohort single-cell RNA sequencing analysis further confirmed these findings and identified a population of neutrophils expressing Vacuolar-type ATPase (V-ATPase) and the chemokine receptor CXCR4 in the nasopharynx. This population of neutrophils preferentially expressed pro-inflammatory genes relevant to phagosomal maturation as well as local reactive oxygen species and reactive nitrogen species production in the nasopharynx of patients with severe outcomes. A four-gene panel defined as a neutrophil signature associated with COVID-19 progression (NSAP) was identified as an early diagnostic predictor of severe COVID-19, which potentially distinguished severe patients from mild cases with influenza, respiratory syncytial virus, dengue virus, or hepatitis B virus infection. NSAP is mainly expressed on CXCR4high neutrophils and exhibits a significant association with the cell fraction of this neutrophil population. This study highlights novel potential therapeutic targets or diagnostic tools for predicting patients at a higher risk of severe outcomes | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a nasopharynx | |
650 | 4 | |a neutrophils | |
650 | 4 | |a predictor | |
650 | 4 | |a severity | |
650 | 7 | |a Adenosine Triphosphatases |2 NLM | |
650 | 7 | |a EC 3.6.1.- |2 NLM | |
700 | 1 | |a Cao, Yingyin |e verfasserin |4 aut | |
700 | 1 | |a Shen, Yunyun |e verfasserin |4 aut | |
700 | 1 | |a Wang, Haiyan |e verfasserin |4 aut | |
700 | 1 | |a Li, Dapeng |e verfasserin |4 aut | |
700 | 1 | |a Yang, Qianting |e verfasserin |4 aut | |
700 | 1 | |a Li, Zhiyan |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Zheng |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 96(2024), 1 vom: 10. Jan., Seite e29328 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
773 | 1 | 8 | |g volume:96 |g year:2024 |g number:1 |g day:10 |g month:01 |g pages:e29328 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.29328 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 96 |j 2024 |e 1 |b 10 |c 01 |h e29328 |